Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non Operating Income (2023 - 2025)

Monte Rosa Therapeutics' Non Operating Income history spans 3 years, with the latest figure at $3.6 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 40.12% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $14.5 million, up 31.9%, while the annual FY2025 figure was $14.5 million, 31.9% up from the prior year.
  • Non Operating Income reached $3.6 million in Q4 2025 per GLUE's latest filing, up from $2.7 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $4.5 million in Q2 2025 to a low of $1.6 million in Q4 2023.
  • Average Non Operating Income over 3 years is $2.8 million, with a median of $2.7 million recorded in 2024.
  • The largest YoY upside for Non Operating Income was 72.52% in 2025 against a maximum downside of 0.8% in 2025.
  • A 3-year view of Non Operating Income shows it stood at $1.6 million in 2023, then surged by 63.44% to $2.6 million in 2024, then soared by 40.12% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Non Operating Income are $3.6 million (Q4 2025), $2.7 million (Q3 2025), and $4.5 million (Q2 2025).